Piramal Pharma posts 17% revenue rise and higher EBITDA margin in Q1 FY27

Piramal Pharma Limited reported a 17% increase in revenue from operations to ₹2,270 crore for the quarter ended 30 June 2026, compared with ₹1,934 crore a year earlier. Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 72% to ₹285 crore, lifting the EBITDA margin to 12.5% from 8.5% in the prior year. The contract development and manufacturing organisation (CDMO) segment grew 19% to ₹1,187 crore, while the complex hospital generics and consumer‑healthcare businesses also delivered double‑digit growth.

Chairperson Nandini Piramal said the company had “started FY27 on a strong note, with all three businesses delivering mid‑to‑high teens revenue growth alongside meaningful EBITDA margin expansion.” The firm highlighted a successful US FDA inspection of its Sellersville facility, confirming its zero OAI status, and noted a one‑time exceptional item of ₹21 crore from insolvency proceeds received in the previous fiscal year.

Piramal expects continued revenue and margin expansion through FY27, citing strong order inflows, pricing discipline and operational excellence across its Indian and overseas sites.